|
US633410A
(en)
|
1898-09-22 |
1899-09-19 |
George A Ames |
Ice-cutter.
|
|
US4235871A
(en)
|
1978-02-24 |
1980-11-25 |
Papahadjopoulos Demetrios P |
Method of encapsulating biologically active materials in lipid vesicles
|
|
US4501728A
(en)
|
1983-01-06 |
1985-02-26 |
Technology Unlimited, Inc. |
Masking of liposomes from RES recognition
|
|
US4957735A
(en)
|
1984-06-12 |
1990-09-18 |
The University Of Tennessee Research Corporation |
Target-sensitive immunoliposomes- preparation and characterization
|
|
US5019369A
(en)
|
1984-10-22 |
1991-05-28 |
Vestar, Inc. |
Method of targeting tumors in humans
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4837028A
(en)
|
1986-12-24 |
1989-06-06 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5004697A
(en)
|
1987-08-17 |
1991-04-02 |
Univ. Of Ca |
Cationized antibodies for delivery through the blood-brain barrier
|
|
WO1989006692A1
(en)
|
1988-01-12 |
1989-07-27 |
Genentech, Inc. |
Method of treating tumor cells by inhibiting growth factor receptor function
|
|
US5055303A
(en)
|
1989-01-31 |
1991-10-08 |
Kv Pharmaceutical Company |
Solid controlled release bioadherent emulsions
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US5271961A
(en)
|
1989-11-06 |
1993-12-21 |
Alkermes Controlled Therapeutics, Inc. |
Method for producing protein microspheres
|
|
US5188837A
(en)
|
1989-11-13 |
1993-02-23 |
Nova Pharmaceutical Corporation |
Lipsopheres for controlled delivery of substances
|
|
US5268164A
(en)
|
1990-04-23 |
1993-12-07 |
Alkermes, Inc. |
Increasing blood-brain barrier permeability with permeabilizer peptides
|
|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
US5254342A
(en)
|
1991-09-30 |
1993-10-19 |
University Of Southern California |
Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
|
|
AU668384B2
(en)
|
1992-03-12 |
1996-05-02 |
Alkermes Controlled Therapeutics, Inc. |
Controlled release ACTH containing microspheres
|
|
US5534496A
(en)
|
1992-07-07 |
1996-07-09 |
University Of Southern California |
Methods and compositions to enhance epithelial drug transport
|
|
US5514670A
(en)
|
1993-08-13 |
1996-05-07 |
Pharmos Corporation |
Submicron emulsions for delivery of peptides
|
|
PT1308456E
(pt)
|
1998-05-06 |
2007-12-03 |
Genentech Inc |
Purificação de anticorpos por cromatografia de permuta iónica
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
JP2006500364A
(ja)
|
2002-08-16 |
2006-01-05 |
イムノージェン インコーポレーテッド |
高い反応性と溶解度を有する架橋剤および小分子薬物の標的化送達用コンジュゲートの調製におけるそれらの使用
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
KR20120064120A
(ko)
|
2004-06-01 |
2012-06-18 |
제넨테크, 인크. |
항체 약물 접합체 및 방법
|
|
KR20140032004A
(ko)
|
2004-07-22 |
2014-03-13 |
제넨테크, 인크. |
Ｈｅｒ２ 항체 조성물
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
NZ602675A
(en)
|
2008-03-18 |
2014-03-28 |
Genentech Inc |
Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
|
|
CN107325182A
(zh)
|
2008-04-02 |
2017-11-07 |
宏观基因有限公司 |
HER2/neu‑特异性抗体和其使用方法
|
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
|
BR122020010643B1
(pt)
|
2011-10-14 |
2022-05-17 |
Array Biopharma Inc |
Dispersão sólida, composições farmacêuticas compreendendo a referida dispersão, usos das composições farmacêuticas e processo de preparação de uma dispersão sólida
|
|
RU2629116C2
(ru)
|
2011-10-14 |
2017-08-24 |
Эррэй Биофарма Инк. |
Полиморфы arry-380, селективного ингибитора erbb2, и фармацевтические составы, содержащие их
|
|
WO2013055874A2
(en)
*
|
2011-10-14 |
2013-04-18 |
Genentech, Inc. |
Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
MX379256B
(es)
|
2013-03-15 |
2025-03-10 |
Regeneron Pharma |
Moleculas biologicamente activas, conjugados de las mismas, y usos terapeuticos.
|
|
WO2014200891A1
(en)
|
2013-06-11 |
2014-12-18 |
THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTEMENT OF HEALTH & HUMAN SERVICES |
Her2-specific monoclonal antibodies and conjugates thereof
|
|
KR102252925B1
(ko)
|
2013-08-26 |
2021-05-18 |
리제너론 파마슈티칼스 인코포레이티드 |
마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
|
|
KR101993136B1
(ko)
|
2013-11-19 |
2019-06-26 |
레메젠 리미티드 |
항-her2 항체 및 이의 접합체
|
|
KR20170042495A
(ko)
|
2013-12-16 |
2017-04-19 |
제넨테크, 인크. |
펩티드모방체 화합물 및 그의 항체-약물 접합체
|
|
HUE029672T2
(en)
|
2014-01-10 |
2017-03-28 |
Synthon Biopharmaceuticals Bv |
Duokarmicin-ADCs for use in the treatment of endometrial cancer
|
|
SI3466976T1
(sl)
|
2014-01-31 |
2021-12-31 |
Daiichi Sankyo Company, Limited |
Anti-her2 konjugat protitelesa-zdravila
|
|
MX2016012830A
(es)
|
2014-04-11 |
2017-01-05 |
Medimmune Llc |
Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
|
|
LT3191135T
(lt)
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
Anti-her2 antikūnai ir imunokonjugatai
|
|
EA034950B1
(ru)
|
2015-03-27 |
2020-04-09 |
Регенерон Фармасьютикалз, Инк. |
Производные майтанзиноида, их конъюгаты и способы использования
|
|
WO2017132173A1
(en)
|
2016-01-25 |
2017-08-03 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
|
SG10201912173RA
(en)
|
2016-10-07 |
2020-02-27 |
Daiichi Sankyo Co Ltd |
Therapy for drug-resistant cancer by administration of anti-her2 antibody/drug conjugate
|
|
CA3060407A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Seattle Genetics, Inc. |
Treatment of her2 positive cancers
|
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|